Glaxosmithkline Pharmaceuticals Ltd.
NSE: GLAXOGlaxosmithkline Pharmaceuticals Ltd.: A 30-second snapshot
GlaxoSmithKline Pharmaceuticals (GLAXO) trades at ₹2,416.7, a trailing PE of 40.5x (forward PE 31.4x), with a 26.86% profit margin and 5-year earnings CAGR of 28.6%. The stock is 31.3% below its 52-week high and 6.3% below its 200-DMA, while remaining marginally above the 50-DMA; RSI stands at 50.2, in neutral territory. A declared dividend of ₹57/share and a global oncology collaboration with Halozyme mark the most recent newsworthy events.
P/E
40.5
Forward P/E
31.4
ROE
—
Debt / Equity
2.09
Profit Margin
+26.9%
Div. Yield
+2.4%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
58/100
News
8 headlines · 5 positive · 0 negative
GSK Pharma declares bumper dividend of Rs 57/share on Q4 profit, revenue uptick — check record date - MSN
MSN
GSK Pharma Q4 Profit Up 5.7% to Rs 277.86 Cr - Rediff MoneyWiz
Rediff MoneyWiz
GSK Pharma Declares Bumper Dividend Of Rs 57/Share On Q4 Profit, Revenue Uptick — Check Record Date - NDTV Profit
NDTV Profit
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets - PR Newswire
PR Newswire
Dividend Stock: MNC pharma major announces one of its highest-ever payouts - CNBC TV18
CNBC TV18
Recent context
- ·Q4 profit grew 5.7% YoY to ₹277.86 crore, and the company declared a dividend of ₹57/share — described as one of its highest-ever payouts — with the record date recently announced.
- ·Halozyme announced a global collaboration and license agreement with GSK to develop subcutaneous formulations across multiple oncology targets, expanding the pipeline optionality.
- ·All 8 recent headlines carry positive or neutral sentiment (5 positive, 3 neutral, 0 negative), concentrated around the dividend announcement and Q4 results — no adverse regulatory or litigation news is visible in the current news window.
Strengths
- +5-year earnings CAGR of 28.6% and a profit margin of 26.86% indicate strong and growing profitability relative to most NSE-listed pharma peers.
- +Debt trend is classified as falling, and FCF was positive in 4 of the available fiscal years, suggesting improving cash generation discipline.
- +Quality score of 51 ranks 2nd among the 6 peers in the sector comparison set (MAXHEALTH 54, SUNPHARMA 50, APOLLOHOSP 42, CIPLA 24, DRREDDY 17).
- +Revenue grew at a 9.7% 5-year CAGR alongside 28.6% earnings CAGR, implying meaningful margin expansion over the period; forward PE of 31.4x is below trailing PE of 40.5x, reflecting improved earnings expectations.
Weaknesses
- −Price is 31.3% below the 52-week high and 6.3% below the 200-DMA (₹2,579.09), indicating sustained medium-term price underperformance relative to recent peaks.
- −Debt-to-equity of 2.09 is elevated; with a consistency score of 48/100 and FCF-positive in only 4 of available years, balance-sheet resilience is not established at the same level as the earnings growth record.
- −ROE data is unavailable, and the analyst dataset covers only 4 analysts with no consensus rating returned — conclusions about capital efficiency and institutional coverage breadth cannot be drawn from available data.
- −Peer comparison is materially incomplete: 4 of 5 comparators lack 1-year price change data and 3 of 5 lack ROE, reducing the reliability of the relative valuation and quality rankings.
Open questions
- ?Does the 28.6% earnings CAGR over 5 years reflect a durable shift in GLAXO's product mix toward higher-margin molecules, or does it partly reflect a low-base recovery from a prior down-cycle?
- ?At a D/E of 2.09 with a falling debt trend, how many more years of free-cash-flow generation would be needed to bring leverage to a level comparable to the median Indian pharma company?
- ?The stock is 31.3% below its 52-week high despite positive earnings and dividend news — what information, if any, might the market be pricing in that is not yet visible in the trailing fundamentals or recent headlines?
- ?With only 4 analysts covering the stock and no consensus rating returned, how representative is the available sell-side data, and what additional sources would give a fuller picture of institutional views on the MNC pharma segment?
Peer comparison: Pharma
Ranks 2 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| GLAXO | Glaxosmithkline Pharmaceuticals Ltd.You're viewing | 40.5 | — | 51 |
| Industry avg | across 5 peers | 47.0 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.6 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.6 | +11.8% | 17 |
Technical state
Current price
₹2,416.70
SMA 50
₹2,412.01
SMA 200
₹2,579.09
RSI (14)
50.2 (neutral)
From 52w high
-31.3%
1Y return
-10.0%
3M return
-7.9%
50-DMA
Above
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumPrice is 31.26% below the 52-week high and 6.3% below the 200-DMA (₹2,579.09 vs current ₹2,416.7), sustaining a medium-term downtrend despite marginal recovery above the 50-DMA (₹2,412.01).
- mediumDebt-to-equity of 2.09 is elevated; with FCF-positive years covering only 4 of available years and a consistency score of 48/100, balance-sheet resilience does not match the pace of earnings growth.
- lowROE data is absent and analyst rating is not returned (4 analysts, no consensus value), limiting conclusions about return-on-equity trajectory and sell-side positioning.
- low4 of 5 peers show no 1-year price change and 3 of 5 show no ROE, making relative-performance and quality rankings partially unreliable. GLAXO ranks 3rd of 6 on PE (40.5x vs sector range 26.6x–72.5x) and 2nd of 6 on quality score (51).
Cross-section contradictions
- News sentiment is positive (5 positive, 0 negative across 8 headlines) and 5-year earnings CAGR is 28.6%, yet the stock is down 10% over 12 months and sits 31.3% below its 52-week high — no single negative catalyst is visible in the news flow to explain the sustained drawdown.
- A trailing profit margin of 26.86% and 5-year earnings CAGR of 28.6% point to a high-quality earnings profile, while a consistency score of 48/100 and absent ROE data introduce uncertainty about whether growth is efficiently compounding equity capital.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 24 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 16 May 2026 · rotates through NIFTY 500 every ~5 days